Repros Therapeutics (RPRX) Earns Daily News Sentiment Score of 0.18

News headlines about Repros Therapeutics (NASDAQ:RPRX) have trended somewhat positive on Monday, Accern reports. Accern scores the sentiment of press coverage by reviewing more than 20 million news and blog sources in real-time. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. Repros Therapeutics earned a news impact score of 0.18 on Accern’s scale. Accern also assigned news headlines about the biotechnology company an impact score of 95 out of 100, meaning that recent press coverage is extremely likely to have an impact on the stock’s share price in the next few days.

Shares of Repros Therapeutics (NASDAQ:RPRX) traded up 7.6200% during trading on Monday, hitting $0.5381. The stock had a trading volume of 496,607 shares. The firm’s market cap is $14.38 million. The firm’s 50-day moving average is $0.51 and its 200-day moving average is $1.03. Repros Therapeutics has a one year low of $0.33 and a one year high of $2.48.

Repros Therapeutics (NASDAQ:RPRX) last issued its quarterly earnings data on Tuesday, May 9th. The biotechnology company reported ($0.22) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.14) by $0.08. The business had revenue of $0.01 million for the quarter. Repros Therapeutics had a negative return on equity of 276.50% and a negative net margin of 49,564.86%. Equities research analysts forecast that Repros Therapeutics will post ($0.76) EPS for the current year.

COPYRIGHT VIOLATION WARNING: “Repros Therapeutics (RPRX) Earns Daily News Sentiment Score of 0.18” was originally reported by WKRB News and is owned by of WKRB News. If you are accessing this article on another website, it was illegally stolen and republished in violation of U.S. and international copyright law. The legal version of this article can be viewed at

Repros Therapeutics Company Profile

Repros Therapeutics, Inc is a biopharmaceutical company focused on the development of new drugs to treat hormonal and reproductive system disorders. The Company’s product candidates include enclomiphene, which is a single isomer of clomiphene citrate, an orally active small molecule compound, and Proellex, which is an orally administered selective blocker of the progesterone receptor in women, for the treatment of uterine fibroids and endometriosis.

Insider Buying and Selling by Quarter for Repros Therapeutics (NASDAQ:RPRX)

This story was originally published by WKRB News ( and is the sole property of WKRB News. If you are reading this article on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. You can view the original version of this story at

Receive News & Ratings for Repros Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Repros Therapeutics Inc. and related companies with's FREE daily email newsletter.


Leave a Reply

© 2006-2017 WKRB News.